Novo Nordisk Appoints New Leader of North American Business

    PRINCETON, N.J., Sept. 4 /CNW/ -- Novo Nordisk, the world's leading
diabetes company, today announced the appointment of Jerzy Gruhn as president
of Novo Nordisk Inc., the company's U.S. affiliate, and senior vice president
of Novo Nordisk North America. Gruhn will replace Martin Soeters, who will
take up the position as senior vice president European region, overseeing the
company's operations in 35 countries. Gruhn is currently vice president of the
Eastern Europe region. The appointments will take effect on January 1, 2008.
    "We are making these changes at a time when Novo Nordisk is doing well in
both Europe and North America and are confident that we have the right
leadership to secure our future growth in the two regions," said Kare Schultz,
executive vice president and chief operating officer.
    During his 11 years with Novo Nordisk, Gruhn has played a critical role
in the company's growth, gaining the company a leading position in Eastern and
Central Europe. In his current position as vice president of the Europe East
region, he overcame strong competitive pressures and adverse market conditions
caused by pricing reforms and reimbursement issues to expand the company's
business in the region to 16 countries with diverse cultures and market
    "North America is not only the world's largest diabetes market, but also
a region populated by people passionate about stopping the diabetes epidemic
here and around the world," said Gruhn. "Novo Nordisk will continue to be a
leader in changing diabetes by embracing a unique business model that allows
us to be socially and environmentally responsible, while achieving fiscal
growth to advance diabetes care."
    Martin Soeters has more than 27 years' experience in Novo Nordisk in
executive management, sales and marketing. Since he took over responsibility
for the company's operations in the North American region in 2000 he has grown
annual sales from $500 million in 2000 to $2.1 billion in 2006. Under his
leadership, Novo Nordisk has successfully launched the company's complete
portfolio of modern insulin, earned a position as the diabetes care leader in
the North American market and at the same time built a strong
biopharmaceuticals business. Today, Novo Nordisk employs more than 3,000
people in the U.S.
    About Novo Nordisk
    Novo Nordisk is a healthcare company with an 84-year history of
innovation and achievement in diabetes care. The company has the broadest
diabetes product portfolio in the industry, including the most advanced
products within the area of insulin delivery systems. In addition to diabetes
care, Novo Nordisk has a leading position within areas such as hemostasis
management, growth hormone therapy, and hormone therapy for women. Novo
Nordisk's business is driven by the Triple Bottom Line: a commitment to
economic success, environmental soundness, and social responsibility to
employees and customers. With headquarters in Denmark, Novo Nordisk employs
more than 25,000 employees in 79 countries, and markets its products in 179
countries. Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock Exchange
under the symbol 'NVO.' For global information, visit; for
United States information, visit

For further information:

For further information: Media, Sean Clements, +1-609-514-8316,, or Investors, Christian Qvist Frandsen, 
+1-609-919-7937,, both of Novo Nordisk Inc. Web Site:        

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890